COMPLETED

Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)

Talk to us

Conditions

Ovarian CancerMobile Application

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will evaluate the use of a mobile application in improving the patient-reported health outcome measures (PROMIS) for patients diagnosed with advanced stage ovarian, fallopian tube, and primary peritoneal cancer. The application will incorporate clinical data from the patient's medical chart as well as capture patient-reported outcome measures on an ongoing basis to better inform physicians and the care team so that necessary interventions may be implemented.

Official Title

Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)

Quick Facts

Study Start:2023-10-17
Study Completion:2025-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05523700

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 90 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Female ≥18 years of age at Screening Visit.
  2. 2. Diagnosed with ovarian cancer, fallopian tube, or primary peritoneal cancer
  3. 3. Undergoing active treatment at some point during the study period including chemotherapy, immunotherapy, targeted agent or hormonal therapy. If active treatment has not yet started at time of screening, active treatment must be anticipated to begin within 30 days of enrollment.
  4. 4. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
  5. 5. Access to IOS or Android-based smart phone
  1. 1. Unwilling or unable to adhere to the protocol
  2. 2. Unwilling or unable to adhere to the informed consent
  3. 3. Age \<18yo
  4. 4. Concurrent non-gynecologic cancer diagnosis requiring active treatment at enrollment
  5. 5. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Contacts and Locations

Principal Investigator

Tiffany Lai, MD
PRINCIPAL_INVESTIGATOR
University of California, Los Angeles

Study Locations (Sites)

UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095-1406
United States

Collaborators and Investigators

Sponsor: Jonsson Comprehensive Cancer Center

  • Tiffany Lai, MD, PRINCIPAL_INVESTIGATOR, University of California, Los Angeles

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-17
Study Completion Date2025-04-30

Study Record Updates

Study Start Date2023-10-17
Study Completion Date2025-04-30

Terms related to this study

Keywords Provided by Researchers

  • Mobile Application

Additional Relevant MeSH Terms

  • Ovarian Cancer